Allarity Therapeutics expands in-house lab to add proteomics, cell line research

Bitget2026/09/28 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Allarity Therapeutics expanded its in-house medical laboratory to add proteomics and cell line research capabilities.
Build-out targets deeper mechanism-of-action work on lead asset stenoparib, a dual PARP and WNT pathway inhibitor in Phase 2.
New services broaden the lab’s external offering, adding to existing transcriptomics research and CLIA clinical testing.
nCounter Pro platform now supports proteomics via the Human Tumor Signaling Protein Panel, measuring about 300 protein targets.
Expansion is not expected to change cash runway, with management pointing to cost efficiencies from bringing more research in-house.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED1001274922) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Allarity Therapeutics expands in-house lab to add proteomics, cell line research

You may also like

Crypto prices